En Es
Categories

Industry News


Seegene Unveils Combination Test at ECCMID 2018

By Labmedica International staff writers
19 Apr 2018

Image: At ECCMID 2018, Seegene showcased its molecular diagnostic system SGSTAR, which allows order-to-report on the same day and enables the running of the combination test (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.

Seegene develops multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Its core enabling technologies are the foundation for M-MoDx tests which can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. The combination test introduced by Seegene at the ECCMID 2018 can detect pathogens for syndromic infectious diseases by simultaneously performing all possible tests for pathogens sharing similar symptoms from the same type of specimen. For instance, in a patient with respiratory symptoms, the combination test can reveal the cause of the disease by simultaneously diagnosing whether the relevant symptoms are caused by tubercule bacillus or pneumococcus. The combination test is available for tuberculosis and pneumonia, as well as for HPV and sexually transmitted infections and full panel tests for gastrointestinal infections.

The company’s molecular diagnostic system SGSTAR, which was also showcased at the ECCMID 2018, is an innovative MDx solution that provides order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, irrespective of the specimen and assay type. With this system solution, the combination test can be concurrently implemented, and the test results can be provided on the very day of the patient's visit to the hospital.

"In order to achieve on-time customized patient care and to foster a comprehensive delivery medical care to patients, a more objective and accurate testing method based on symptoms and samples is necessary. We believe that Seegene's combination test will be a breakthrough in achieving this," said Dr. Jong-Yoon Chun, founder and CEO of Seegene. "If the combination test is broadly applied, the exact cause of infectious diseases can be identified and treated. This not only contributes to the improvement in patient care, but also medical institutions and reimbursement system can save time and costs, which could create new value-added to the molecular diagnostic industry."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
09 Jan 2018
Seegene Develops World’s First Multiplex MDx Assays with AI System
Seegene Inc., a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

21 Jan 2022
Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases
The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application of immunofluorescence assays in clinical diagnostics and research, and growing investments and expenditure in healthcare sector.
Read More
21 Jan 2022
Global Digital X-Ray Systems Market to Be Driven by AI-Based Systems and Robotic Devices
The global digital X-ray systems market was valued at USD 11.74 billion in 2020 and is expected to grow at a CAGR of 7.45% during the forecast period 2021 to 2026, due to the rising number of cancer patients and increasing cases of orthopedic diseases/tumors, cardiovascular diseases (CVD), pneumonia, and dental disorders, among others.
Read More
20 Jan 2022
Illumina and Boehringer Ingelheim Partner to Develop Companion Diagnostics (CDx) for Cancer Treatment
Illumina Inc. (San Diego, CA, USA) has entered into a partnership with Boehringer Ingelheim (Ingelheim am Rhein, Germany; www.boehringer-ingelheim.com) to develop companion diagnostics (CDx) for several programs in the latter’s oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.
Read More
20 Jan 2022
Thermo Fisher and Oncocyte to Jointly Develop IVD Test Kits and Companion Diagnostic Tests in Precision Oncology
Oncocyte Corporation (Irvine, CA, USA) has entered into a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s (Waltham, MA, USA) Ion Torrent Genexus System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System.
Read More
18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
11 Jan 2022
J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions
The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA; www.microsoft.com) to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions